Chidi Samuel| Nigeria on Saturday night confirmed 265 new coronavirus cases bringing the countr’s toll 7526.
The Nigeria Centre For Disease Control in a tweet via its verified Twitter handle said Lagos recorded 133 new csaes, Oyo 34, Edo 28, Ogun 23, FCT 22, Plateau 6 and Kaduna 5.
Other states thate recorded new infections include, Bornu 3, Niger 3, Kwara, Bauchi, and Anambra recorded 2 infections each.
According to the health agency, Nigeria currently has 7526 confirmed cases of the dreaded virus with 2174 discharges and 221 deaths.
The tweet read, ”265 new cases of #COVID19;
133-Lagos
34-Oyo
28-Edo
23-Ogun
22-FCT
6-Plateau
5-Kaduna
3-Borno
3-Niger
2-Kwara
2-Bauchi
2-Anambra
2-Enugu
7526 cases of #COVID19 in Nigeria”.
Discharged: 2174
Deaths: 221
-Anti-viral drug effective in the treatment of Coronavirus- Study
Meanwhile, Anti-viral drug remdesivir cuts recovery times in coronavirus patients, according to the full results of a trial published Friday night, three weeks after America’s top infectious diseases expert said the study showed the medication has “clear-cut” benefits.
Complete results from the research, which was carried out by US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published by leading medical periodical the New England Journal of Medicine.
The United States authorized the emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe is considering following suit.
The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized COVID-19 patients compared to a placebo in clinical tests on just over a thousand patients across 10 countries.
On April 29, NIAID director Anthony Fauci, who has become the US government’s trusted face on the coronavirus pandemic, said preliminary evidence indicated remdesivir had a “clear-cut, significant and positive effect in diminishing the time to recovery.”
The National Institutes of Health, of which the NIAID is a part, said Friday in a statement online that investigators found “remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen.”
But the authors of the trial wrote that the drug did not prevent all deaths.
“Given high mortality despite the use of remdesivir, it is clear that treatment with an anti-viral drug alone is not likely to be sufficient,” they said.
About 7.1 percent of patients given remdesivir in the trial group died within 14 days — compared with 11.9 percent in the placebo group.
However, the result is just below the statistical reliability threshold, meaning it could be down to chance rather than the capability of the drug.
With AFP report
Leave a Reply